Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 4/20 | 0.63 |
| ▸ | MCHR1 | Q99705 | 13/20 | 0.61 |
| ▸ | PLAU | P00749 | 1/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | CCR6 | P51684 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL5753024 | 0.98 | NCF1 (0.61) | NCF1MCHR1PLAUKDM4EMAPT | |
| SCHEMBL5884112 | 0.94 | NCF1 (0.67) | NCF1MCHR1PLAU | |
| SCHEMBL729315 | 0.84 | MEN1 (0.54) | NCF1PLAUKDM4EMAPTCCR6 | |
| SCHEMBL9951781 | 0.83 | MEN1 (0.55) | NCF1KDM4EMAPTCCR6 | |
| SCHEMBL7256252 | 0.82 | MCHR1 (0.68) | NCF1MCHR1 | |
| SCHEMBL28284853 | 0.81 | MEN1 (0.59) | KDM4EMAPTCCR6 | |
| SCHEMBL3949886 | 0.81 | MEN1 (0.78) | KDM4EMAPTCCR6 | |
| SCHEMBL731221 | 0.81 | KDM4E (0.56) | KDM4EMAPTCCR6 | |
| SCHEMBL18438857 | 0.81 | MEN1 (0.61) | KDM4EMAPTCCR6 | |
| SCHEMBL5884239 | 0.81 | MCHR1 (0.57) | NCF1MCHR1PLAU |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6989392-B2 | 2-Aminoquinolines as melanin concentrating hormone receptor antagonists | ABBOTT LABORATORIES (US) | 2006-01-24 | — | — | US | claimed |
| US-20040063756-A1 | 2-Aminoquinolines as melanin concentrating hormone receptor antagonists | ABBVIE INC. | 2004-04-01 | — | — | US | claimed |
| WO-2003105850-A1 | 2-AMINOQUINOLINES AS MELANIN CONCENTRATING HORMONE RECEPTOR ANTAGONISTS | ABBOTT LABORATORIES (US) | 2003-12-24 | — | — | WO | claimed |
| EP-1542692-B1 | AMINOPYRIMIDINE DERIVATIVES FOR USE AS VANILLOID RECEPTOR LIGANDS FOR THE TREATMENT OF PAIN | AMGEN INC (US) | 2011-01-05 | — | — | EP | disclosed |
| EP-1542692-B1 | AMINOPYRIMIDINE DERIVATIVES FOR USE AS VANILLOID RECEPTOR LIGANDS FOR THE TREATMENT OF PAIN | AMGEN INC (US) | 2011-01-05 | — | — | EP | disclosed |
| EP-2270006-A1 | Pyridazine derivatives useful as vanilloid receptor ligands | Amgen, Inc (US) | 2011-01-05 | — | — | EP | disclosed |
| EP-2270006-A1 | Pyridazine derivatives useful as vanilloid receptor ligands | Amgen, Inc (US) | 2011-01-05 | — | — | EP | disclosed |
| US-7524874-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2009-04-28 | — | — | US | disclosed |
| US-7524874-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2009-04-28 | — | — | US | disclosed |
| US-7524874-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2009-04-28 | — | — | US | disclosed |
| US-7396831-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2008-07-08 | — | — | US | disclosed |
| EP-1542692-A1 | AMINO-PYRIDINE, -PYRIDINE AND PYRIDAZINE DERIVATIVES FOR USE AS VANILLOID RECEPTOR LIGANDS FOR THE TREATMENT OF PAIN | Amgen Inc. (US) | 2005-06-22 | — | — | EP | disclosed |
| US-20040082780-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN, INC. | 2004-04-29 | — | — | US | disclosed |
| US-20040063756-A1 | 2-Aminoquinolines as melanin concentrating hormone receptor antagonists | ABBVIE INC. | 2004-04-01 | — | — | US | disclosed |
| US-20040038969-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN, INC. | 2004-02-26 | — | — | US | disclosed |
| WO-2004014871-A1 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | AMGEN INC. (US) | 2004-02-19 | — | — | WO | disclosed |
| WO-2003105850-A1 | 2-AMINOQUINOLINES AS MELANIN CONCENTRATING HORMONE RECEPTOR ANTAGONISTS | ABBOTT LABORATORIES (US) | 2003-12-24 | — | — | WO | disclosed |
| WO-2003099284-A1 | AMINO-PYRIDINE, -PYRIDINE AND PYRIDAZINE DERIVATIVES FOR USE AS VANILLOID RECEPTOR LIGANDS FOR THE TREATMENT OF PAIN | AMGEN INC. (US) | 2003-12-04 | — | — | WO | disclosed |
| EP-1235825-A1 | NOVEL BENZOIMIDAZOLE DERIVATIVES USEFUL AS ANTIPROLIFERATIVE AGENTS | Pfizer Products Inc. (US) | 2002-09-04 | — | — | EP | disclosed |
| WO-2001040217-A1 | NOVEL BENZOIMIDAZOLE DERIVATIVES USEFUL AS ANTIPROLIFERATIVE AGENTS | PFIZER PRODUCTS INC. (US) | 2001-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063756-A1 | 2-Aminoquinolines as melanin concentrating hormone receptor antagonists | MCHR1, MCHR2, MC1R | NCF1 3219/4885MCHR1 1/4885PLAU 3907/4885 |
| US-20040038969-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV2, TRPV3 | NCF1 2546/4885MCHR1 455/4885PLAU 3213/4885 |
| US-20040082780-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV2, TRPV3 | NCF1 2644/4885MCHR1 465/4885PLAU 3149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.